A Randomized Phase II Study Adding Axitinib to Pemetrexed‐Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single‐Center Trial Combining Clinical and Translational Outcomes

[1]  B. Milleron,et al.  Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial. , 2015 .

[2]  S. Ou,et al.  Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality‐of‐life assessments , 2014, Cancer.

[3]  G. Scagliotti,et al.  Randomized phase II study of pemetrexed/cisplatin with or without axitinib for non-squamous non-small-cell lung cancer , 2014, BMC Cancer.

[4]  T. Choueiri,et al.  Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. , 2013, Critical reviews in oncology/hematology.

[5]  R. Motzer,et al.  Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[6]  H. Groen,et al.  Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. , 2013, The Lancet. Oncology.

[7]  R. Herbst,et al.  Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours , 2012, British Journal of Cancer.

[8]  A. Musk,et al.  A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  S. Armato,et al.  Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Vokes,et al.  Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). , 2012, Lung cancer.

[11]  A. Wozniak,et al.  Phase II Study of Cediranib in Patients with Malignant Pleural Mesothelioma: SWOG S0509 , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  L. Seymour,et al.  Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  H. Rugo,et al.  Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Rini,et al.  Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors , 2011, Clinical Cancer Research.

[15]  E. Van Cutsem,et al.  Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. , 2011, The Lancet. Oncology.

[16]  J. Waltenberger,et al.  A Disintegrin and Metalloprotease 10 Is a Novel Mediator of Vascular Endothelial Growth Factor–Induced Endothelial Cell Function in Angiogenesis and Is Associated With Atherosclerosis , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[17]  N. Reinmuth,et al.  Current data on predictive markers for anti-angiogenic therapy in thoracic tumours , 2010, European Respiratory Journal.

[18]  P. Jänne,et al.  A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307 , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  F. Guadagni,et al.  Thromboembolic events in patients treated with anti-angiogenic drugs. , 2009, Current vascular pharmacology.

[20]  J. Ambati,et al.  Alternatively spliced VEGF receptor-2 is an essential endogenous inhibitor of lymphatic vessels , 2009, Nature Medicine.

[21]  S. Rafii,et al.  VEGF-A Stimulates ADAM17-Dependent Shedding of VEGFR2 and Crosstalk Between VEGFR2 and ERK Signaling , 2008, Circulation research.

[22]  J. Christensen,et al.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy , 2007, Proceedings of the National Academy of Sciences.

[23]  G. Giaccone,et al.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  U. Gatzemeier,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Griffioen,et al.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.

[26]  E. van Marck,et al.  Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression , 1999, The Journal of pathology.

[27]  R. K. Bright,et al.  VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours , 1999, British Journal of Cancer.

[28]  H. Strander,et al.  Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. , 1998, Anticancer research.

[29]  B. Weyn,et al.  EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA , 1997, The Journal of pathology.

[30]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.